Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021)

Avalo Therapeutics (AVTX) has disclosed Liabilities from Discontinued Operations for 3 consecutive years, with 10000.0 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Liabilities from Discontinued Operations changed N/A year-over-year to 10000.0, compared with a TTM value of 10000.0 through Sep 2021, changed N/A, and an annual FY2020 reading of 1341000.0, down 23.59% over the prior year.
  • Liabilities from Discontinued Operations was 10000.0 for Q3 2021 at Avalo Therapeutics, down from 98000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 1755000.0 in Q4 2019 and bottomed at 10000.0 in Q3 2021.
  • Average Liabilities from Discontinued Operations over 3 years is 682600.0, with a median of 209000.0 recorded in 2021.
  • Peak annual rise in Liabilities from Discontinued Operations hit 23.59% in 2020, while the deepest fall reached 23.59% in 2020.
  • Year by year, Liabilities from Discontinued Operations stood at 1755000.0 in 2019, then decreased by 23.59% to 1341000.0 in 2020, then plummeted by 99.25% to 10000.0 in 2021.
  • Business Quant data shows Liabilities from Discontinued Operations for AVTX at 10000.0 in Q3 2021, 98000.0 in Q2 2021, and 209000.0 in Q1 2021.